Admin Control Panel

New Post | Settings | Change Layout | Edit HTML | Edit posts | Sign Out


March20 podcast Dr Hazen
anti-TMA pill in a year or 2 ? (scroll 12 mins)

Additional info:
MEBO Karen
at UK Findacure conf 2020

Scroll down and select country

MEBO Map Testing & Meetups

Full details :
want listed ? contact

MEBO - UBIOME study 2018



MEBO Gut Microbiome Study
"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"
Funded by uBiome Research Grant

"Microbial Basis of Systemic Malodor and PATM Conditions (PATM)"

Dynamics of the Gut Microbiota in
Idiopathic Malodor Production

Started May 2018 - Ongoing

Current people sent kits : 100/100
3 kits per person


Participation info : LINK English

MEBO Private Facebook Group
to join : go to
or contact
Join/Watch the weekly
BO Sufferers Podcasts



TMAU Petition world
TMAU UK end total:262
TMAU UK ends 23/01/20
TMAU Petition USA end total 204
USA : Moveon open
TMAU (Dominican)
Metabolomic Profiling Study

Start : Aug 2016
Stage 1 : 27 Canadian volunteers to test
Latest click here (26 oct) :
17 samples returned

Note : Stage 1 is Canada only.
Return cut-off date : passed
Analysis can take 6/8 weeks
Analysis start in/before Nov
MEBO Research is a
NORD Member Organization
See RareConnect TMAU

Popular Posts (last 30 days)

Upcoming get-togethers

Let us know if you want a meetup listed
Follow MeBOResearch on Twitter

Blog Archive

Denver TMAU Test Lab survey click here
click to Read more/less

USA survey for anyone who wants to improve Denver TMAU test

begun : Dec22
end : no ending for now

A trainee genetic counselor is working at the Denver TMAU test lab. Probably as part of her training. As a project she wishes feedback on any aspect of the Denver TMAU test and process. You can fill in the survey and/or email her (email address is in survey). It's meant for USA people, but perhaps others can give their view too (as we have so few opportunities).

quote from her rareconnect post

"Hello all! I wanted to make you aware of a research study being conducted to better understand the experience and needs of individuals with trimethylaminuria with a goal of being able to create improved patient and healthcare provider education materials. Any participation is completely voluntary and all responses remain confidential. Feel free to use the contact information within the link with any questions or share the survey with others with TMAU."

see this post for more details

Wednesday, January 11, 2012

Pharmacogenetic testing and research

Athough MEBO Research does not intend to start pharmacogenetic testing at the present time, it is noteworthy how significant a person’s ability to metabolize medication is in order to obtain the desired therapeutic effect intended by the physician. Pharmaceutical companies have been concerned with this concept, as noted in the AmpliChip CYP450 Test from the pharmaceutical company, Roche. This test is the world’s first microarray-based parmacogenomic test cleared for clinical use. According to Roche,

The AmpliChip CYP450 Test provides comprehensive detection of gene variations — including deletions and duplications — for the CYP2D6 and CYP2C19 genes, which play a major role in the metabolism of an estimated 25% of all prescription drugs. It is intended to be an aid to clinicians in determining therapeutic strategy and treatment dose for therapeutics metabolized by the CYP2D6 or CYP2C19 gene product.

It would be interesting to look into the possibility of carrying out genetic research sometime in the future to find specific gene types that determine how medicines are metabolized in sufferers of body odor and halitosis conditions in comparison to a non-sufferer control group. Perhaps this would be of mutual interest to both, pharmaceutical companies and sufferers, especially those whose physician wants to prescribe psychiatric medication or are taking other medications for other medical conditions. Perhaps MEBO might be able to tap into pharmaceutical company funding for such a study within the next couple of years.

This explosion of biologic information about the proteins and pathways relevant to cellular physiology and disease has stimulated biotechnology and pharmaceutical researchers to assign top priority to identification and validation of key targets (known or novel) to develop therapies for the many remaining diseases. Hypothesis-based biological research is now supplemented with multidisciplinary approaches to systems and circuit-based biology that integrate bioinformatics, genomic databases, and cellular and molecular biology with the traditional drug discovery disciplines of physiological biochemistry, pharmacology, and medicinal chemistry. As a consequence, interventional strategies now include recombinant proteins, monoclonal antibodies, peptides, and small organic molecules as drug candidates. The goal is to expedite the testing of novel therapeutic hypotheses in humans and to develop strategies to identify optimal therapy for individual patients.

Additional information:

halitosis research
María de la Torre
Founder and Executive Director

A Public Charity
MEBO's Blog (English)
El Blog de MEBO (español)
The MEBO Forum Please sign the MEBO Petition

body odor petition
MEBO Research


Post a Comment